Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.60 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 7/20 | 0.44 |
| ▸ | CES1 | P23141 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11795301 | 1.00 | CES2 (0.60) | CES2LPAR1LPAR3MEN1KMT2A | |
| SCHEMBL5146085 | 1.00 | CES2 (0.60) | CES2LPAR1LPAR3MEN1KMT2A | |
| SCHEMBL11534492 | 0.98 | CES2 (0.57) | CES2LPAR1LPAR3MEN1KMT2A | |
| SCHEMBL10970451 | 0.92 | CES2 (0.48) | CES2LPAR1LPAR3MEN1KMT2A | |
| SCHEMBL21802245 | 0.84 | CES2 (0.66) | CES2LPAR1LPAR3MEN1KMT2A | |
| SCHEMBL28327210 | 0.84 | CES2 (0.66) | CES2LPAR1LPAR3MEN1KMT2A | |
| SCHEMBL14533801 | 0.83 | CES2 (0.38) | CES2MEN1KMT2AEPHX1FAAH | |
| SCHEMBL23578179 | 0.82 | CES2 (0.58) | CES2LPAR1LPAR3MEN1KMT2A | |
| SCHEMBL20654753 | 0.82 | CES2 (0.58) | CES2LPAR1LPAR3MEN1KMT2A | |
| SCHEMBL20654846 | 0.82 | CES2 (0.58) | CES2LPAR1LPAR3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2021252640-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-0046082-A2 | 8-Aza-16,16-difluoroprostanoids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | CES2 2523/4885LPAR1 4375/4885LPAR3 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.